From September 2019 through March 2020, the upcoming ACI series includes programs in the following cities*:

- Cleveland - Sept. 5, 2019
- Chicago - Sept. 28, 2019
- Boston - Oct. 10, 2019
- Buffalo, N.Y. - Oct. 26, 2019
- San Francisco - Nov. 14, 2019
- Nashville - Dec. 4, 2019
- Birmingham, Ala.
- Charlotte, N.C.
- Philadelphia
- San Antonio
- San Diego
- Tampa, Fla.
- Tucson, Ariz.
- Washington, D.C.
- Vancouver, B.C.

*Please visit sitcancer.org/aci for more information.

ACI PROGRAM TAKEAWAYS

ACIs are presented by local authorities in tumor immunology and cancer immunotherapy and cover the following topics:

- Treating patients with FDA-approved immunotherapies
- Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identifying and managing irAEs
- Employing strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Applying foundational knowledge for clinical implementation of SITC’s Cancer Immunotherapy Guidelines
- Anticipating forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Recognizing common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

For full accreditation information and to register for these events, please visit sitcancer.org/aci

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Bristol-Myers Squibb, Incyte Corporation and Merck & Co., Inc. (as of June 26, 2019).
WHY ATTEND?

- Earn CME, CPE and CNE credits and MOC points
- Attend for FREE if you are a healthcare professional, student, patient or patient advocate
- Hear from and network with local experts in tumor immunology and cancer immunotherapy

ACCREDITATION INFORMATION

**AMA Credit Designation**
This activity has been approved for AMA PRA Category 1 Credit(s)™.

**Pharmacist Credit Designation**
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

**Nursing Credit Designation**
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

Thank you to our dedicated organizers who make our ACI live programs so engaging and impactful:

**CLEVELAND-SEPT. 5, 2019**
Brian Rini, MD – Cleveland Clinic Cancer Center
Pauline Funchain, MD – Cleveland Clinic Cancer Center
Jung-Min Song, CNP, RN – Cleveland Clinic Cancer Center

**CHICAGO-SEPT. 28, 2019**
Derek A. Wainwright, PhD – Northwestern University
Jeffrey A. Sosman, MD – Northwestern University
Lisa Ha, RN – Northwestern Medicine

**BOSTON-OCT. 10, 2019**
David F. McDermott, MD – Beth Israel Deaconess Medical Center
Elizabeth Buchbinder, MD, PhD – Dana-Farber Cancer Institute
Virginia Seery, MSN, RN, ANP-BC – Beth Israel Deaconess Medical Center

**BUFFALO, N.Y.-OCT. 26, 2019**
Marc S. Ernstoff, MD – Roswell Park Comprehensive Cancer Center
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center
Cheryl Raczyk, PA – Roswell Park Comprehensive Cancer Center

**SAN FRANCISCO-NOV. 4, 2019**
Terence Friedlander, MD – University of California San Francisco
Katy K. Tsai, MD – University of California San Francisco
Lissa Gray, NP – University of California San Francisco

**NASHVILLE, TENN.-DEC. 4, 2019**
Anil Shanker, PhD – Meharry Medical College School of Medicine
Suzanne Jones, PharmD – Sarah Cannon
Jeffrey C. Rathmell, PhD – Vanderbilt University School of Medicine

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2019-2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Bristol-Myers Squibb, Incyte Corporation and Merck & Co., Inc. (as of June 26, 2019).

For full accreditation information and to register for these events, please visit sitcancer.org/aci